Transgene (XPAR:TNG) FFO


XPAR:TNG Transgene SA XPAR:TNG
46 GF Score
Price €0.73
GF Value €0.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:TNG
46GF Score
Transgene SA XPAR:TNG
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene (XPAR:TNG) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.73 is trading 37.5% above its estimated GF Value™ of €0.53. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for XPAR:TNG:

  • FFO:
  • GF Value™: €0.53 vs. price of €0.73 (37.5% above fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the XPAR:TNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
46GF Score

Get the complete analysis for XPAR:TNG

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.73
Price
€0.53
GF Value